{"id":"tak-438","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital amputation"},{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"},{"rate":"null","effect":"Increased risk of urinary tract infections"}]},"_chembl":{"chemblId":"CHEMBL2064032","moleculeType":"Small molecule","molecularWeight":"461.47"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, TAK-438 reduces glucose reabsorption in the kidneys, leading to decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating type 2 diabetes.","oneSentence":"TAK-438 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:17.833Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07267260","phase":"PHASE2","title":"Evaluating the Efficacy of Vonoprazan in Preventing Post-Endoscopic Variceal Band Ligation Ulcers: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"King Edward Medical University","startDate":"2025-12-16","conditions":"Cirrhoses, Liver","enrollment":154},{"nctId":"NCT03214081","phase":"","title":"Special Drug Use Surveillance of Vonoprazan for \"Maintenance Therapy of Reflux Esophagitis: Long-term Use\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-03-01","conditions":"Reflux Esophagitis","enrollment":1237},{"nctId":"NCT04198363","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-04-30","conditions":"Helicobacter Pylori","enrollment":510},{"nctId":"NCT04753437","phase":"PHASE1","title":"A Study of Vonoprazan in Adults With Helicobacter Pylori","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-04-06","conditions":"Helicobacter Pylori","enrollment":44},{"nctId":"NCT03214198","phase":"","title":"Special Drug Use Surveillance of Vonoprazan for \"Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-09-01","conditions":"A History of Gastric or Duodenal Ulcers","enrollment":1304},{"nctId":"NCT03050307","phase":"PHASE3","title":"Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-17","conditions":"Gastric Ulcer","enrollment":234},{"nctId":"NCT03050359","phase":"PHASE3","title":"Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-05","conditions":"Duodenal Ulcer","enrollment":533},{"nctId":"NCT03808493","phase":"PHASE1","title":"A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet","status":"COMPLETED","sponsor":"Takeda","startDate":"2019-01-30","conditions":"Japanese Healthy Adult Male","enrollment":48},{"nctId":"NCT03214094","phase":"","title":"Special Drug Use Surveillance of Vonoprazan for \"Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin: Long-term Use\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-09-01","conditions":"Gastric or Duodenal Ulcers","enrollment":1119},{"nctId":"NCT02388737","phase":"PHASE3","title":"Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-04-01","conditions":"Erosive Esophagitis","enrollment":703},{"nctId":"NCT02743949","phase":"PHASE2","title":"Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-07-14","conditions":"Gastroesophageal Reflux","enrollment":256},{"nctId":"NCT03214952","phase":"","title":"Drug Use Surveillance of Vonoprazan for \"Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-03-01","conditions":"Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis","enrollment":3183},{"nctId":"NCT03456960","phase":"PHASE1","title":"A Study to Evaluate the Bioequivalence (BE) and the Food Effect of TAK-438ASA Tablet","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-03-08","conditions":"Healthy Volunteers","enrollment":276},{"nctId":"NCT02954848","phase":"PHASE3","title":"Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-11-15","conditions":"Non-erosive Gastroesophageal Reflux Disease","enrollment":484},{"nctId":"NCT02388724","phase":"PHASE3","title":"Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-03-24","conditions":"Erosive Esophagitis","enrollment":481},{"nctId":"NCT03219723","phase":"","title":"Drug Use Surveillance of Takecab for \"Supplement to Helicobacter Pylori Eradication\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-09-01","conditions":"Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other","enrollment":560},{"nctId":"NCT03085836","phase":"PHASE1","title":"A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-19","conditions":"Healthy Participants","enrollment":33},{"nctId":"NCT02892409","phase":"PHASE1","title":"TAK-438 Bismuth Drug Interaction Study","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-09-05","conditions":"Helicobacter Pylori","enrollment":30},{"nctId":"NCT02037477","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-01","conditions":"Healthy Volunteers","enrollment":20},{"nctId":"NCT02774902","phase":"PHASE1","title":"TAK-438_110 Drug Interaction With Cytochrome P450 3A4 (CYP3A4) Inhibitor Clarithromycin","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-08","conditions":"Healthy Volunteers","enrollment":16},{"nctId":"NCT02141711","phase":"PHASE1","title":"TAK-438 - Safety, Blood Levels & Effects of Repeated Doses","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-10","conditions":"Erosive Esophagitis(EE), Gastroesophageal Reflux Disease (GERD)","enrollment":48},{"nctId":"NCT02141698","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese Subjects","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-10","conditions":"Dose Finding Study","enrollment":73},{"nctId":"NCT01456247","phase":"PHASE3","title":"Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-03","conditions":"Gastric Ulcers, Duodenal Ulcers","enrollment":439},{"nctId":"NCT01456260","phase":"PHASE3","title":"Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-09","conditions":"Gastric Ulcers, Duodenal Ulcers","enrollment":406},{"nctId":"NCT02123953","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-10","conditions":"Dose Finding Study","enrollment":60},{"nctId":"NCT02123927","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of TAK-438 in Healthy Male Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-09","conditions":"Ascending Single Dose Study","enrollment":108},{"nctId":"NCT01568385","phase":"PHASE3","title":"A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-04","conditions":"Gastric Ulcer, Duodenal Ulcer","enrollment":30},{"nctId":"NCT01630746","phase":"PHASE3","title":"A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-07","conditions":"Erosive Esophagitis","enrollment":19},{"nctId":"NCT01568398","phase":"PHASE3","title":"A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-05","conditions":"Gastric Ulcer, Duodenal Ulcer","enrollment":27},{"nctId":"NCT01452750","phase":"PHASE3","title":"Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-10","conditions":"Gastric Ulcers, Duodenal Ulcers","enrollment":642},{"nctId":"NCT01452763","phase":"PHASE3","title":"Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-10","conditions":"Gastric Ulcers, Duodenal Ulcers","enrollment":621},{"nctId":"NCT01505127","phase":"PHASE3","title":"Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-01","conditions":"H. Pylori Infection","enrollment":650},{"nctId":"NCT01452776","phase":"PHASE3","title":"Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-09","conditions":"Erosive Esophagitis","enrollment":305},{"nctId":"NCT01459367","phase":"PHASE3","title":"Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-10","conditions":"Erosive Esophagitis","enrollment":607},{"nctId":"NCT01452724","phase":"PHASE3","title":"Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-10","conditions":"Duodenal Ulcer","enrollment":372},{"nctId":"NCT01474369","phase":"PHASE3","title":"Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-12","conditions":"Non-erosive Gastroesophageal Reflux Disease","enrollment":827},{"nctId":"NCT01452711","phase":"PHASE3","title":"Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-11","conditions":"Gastric Ulcer","enrollment":482},{"nctId":"NCT01452698","phase":"PHASE3","title":"Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis","status":"COMPLETED","sponsor":"Takeda","startDate":"","conditions":"Erosive Esophagitis","enrollment":409}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vonoprazan"],"phase":"phase_3","status":"active","brandName":"TAK-438","genericName":"TAK-438","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAK-438 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":6},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}